. . . . .

# CD32 Monoclonal Antibody (6C4 (CD32)), Functional Grade, eBioscience™

Product Details	
Size	50 µg
Species Reactivity	Human
Published Species	Human
Host/Isotype	Mouse / IgG1, kappa
Recommended Isotype Control	Mouse IgG1 kappa Isotype Control (P3.6.2.8.1), Functional Grade, eBioscience™
Class	Monoclonal
Туре	Antibody
Clone	6C4 (CD32)
Conjugate	Functional Grade
Form	Liquid
Concentration	1 mg/mL
Purification	Affinity chromatography
Storage buffer	PBS, pH 7.2
Contains	no preservative
Storage conditions	4° C
RRID	AB_1311188

Applications	Tested Dilution	Publications
Immunohistochemistry (IHC)	-	1 Publication
Flow Cytometry (Flow)	1 µg/test	2 Publications
Functional Assay (FN)	Assay-Dependent	-
Inhibition Assays (IA)	-	1 Publication
Blocking Assay (BLOCK)	-	2 Publications

#### **Product Specific Information**

Description: This 6C4 monoclonal antibody reacts with human CD32 (also known as Fc gammaRII). This antibody recognizes two isoforms of the receptor, Fc gammaRIIA and Fc gammaRIIB. These 40-kDa polymorphic transmembrane glycoproteins are expressed on B cells, granulocytes, monocytes, macrophages, and platelets. Moreover, these receptors are detected on natural killer cells. CD32 enables interaction between Fc gammaRII-expressing cells and opsonized antigen or IgG-containing immune complexes. Both receptors exhibit low affinity towards IgG and play a role in inflammation and autoimmune disease. This clone has been reported to inhibit Ig binding in a rosette blocking assay.

Applications Tested: This 6C4 (CD32) antibody has been tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at less than or equal to 1  $\mu$ g per test. A test is defined as the amount ( $\mu$ g) of antibody that will stain a cell sample in a final volume of 100  $\mu$ L. Cell number should be determined empirically but can range from 10^5 to 10^8 cells /test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.

Storage and handling: Use in a sterile environment.

Filtration: 0.2 µm post-manufacturing filtered.


1

Purity: Greater than 90%, as determined by SDS-PAGE.

Endotoxin Level: Less than 0.001 ng/ $\mu$ g antibody, as determined by LAL assay.

Aggregation: Less than 10%, as determined by HPLC.

## Product Images For CD32 Monoclonal Antibody (6C4 (CD32)), Functional Grade, eBioscience™



#### CD32 Antibody (16-0329-81) in Flow

Staining of normal human peripheral blood cells with Anti-Human CD19 APC (Product # 17-0199-42) and 0.5 µg of Mouse IgG1 K Isotype Control Functional Grade Purified (Product # 16-4714-82) (left) or 0.5 µg of Anti-Human CD32 Functional Grade Purified (right) followed by F (ab')2 Anti-Mouse IgG PE (Product # 12-4010-82).Cells in the lymphocyte gate were used for analysis.

#### **□**6 References

#### Immunohistochemistry (1)

#### PloS one

# Mechanisms controlling the effects of bevacizumab (avastin) on the inhibition of early but not late formed corneal neovascularization.

"Published figure using CD32 monoclonal antibody (Product # 16-0329-81) in Immunohistochemistry" Authors: Chen WL,Chen YM,Chu HS,Lin CT,Chow LP,Chen CT,Hu FR

#### Flow Cytometry (2)

Journal of neurovirology	<b>Year</b> 2017
Immortalization of primary microglia: a new platform to study HIV	
regulation in the central nervous system.	
"Published figure using CD32 monoclonal antibody (Product # 16-0329-81) in Flow Cytometry"	
Authors: Garcia-Mesa Y,Jay TR,Checkley MA,Luttge B,Dobrowolski C,Valadkhan S,Landreth GE,Karn J,Alvarez- Carbonell D	

mAbs	<b>Year</b> 2015
Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-	
TNF monoclonal antibody. A potential strategy to enhance anti-TNF therapy.	
"16-0329 was used in Flow cytometry/Cell sorting to demonstrate the specific blocking of CD64 by H22(scFv) could be used as a mechanism for potentiating the effect of anti-TNF antibodies."	
Authors: Hristodorov D,Mladenov R,Brehm H,Fischer R,Barth S,Thepen T	

#### Inhibition Assays (1)

Frontiers in immunology	Year	
IFN Enhances CD64-Potentiated Phagocytosis of Treponema pallidum	2019	
Opsonized with Human Syphilitic Serum by Human Macrophages.	Species	
"16-0329-81 was used in Inhibition Assays to determine the role of IFN-activated macrophages in early syphilis."	Human	
Authors: Hawley KL,Cruz AR,Benjamin SJ,La Vake CJ,Cervantes JL,LeDoyt M,Ramirez LG,Mandich D,Fiel-Gan M, Caimano MJ,Radolf JD,Salazar JC		

#### More applications with references on thermofisher.cn

### BLOCK (2)

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization. Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set forth in the Production documentation, specifications and/or accompanying package inserts ("Documentation"). No claim of suitability for use in applications regulated by FDA is made. The warranty pervided herein is valid only when used by property trained individuals. Unless otherwise stated in the Documentation, this warranty ger from date of shipment when the Product is subjected to normal, proper and intended usage. This warranty des not extend to anyone other than the Buyer. Any model or sample furnished to Buyer is merely illustrative of the general type and quality of goods and does not represent that any Product will conform to such model or sample furnished to Buyer is morely illustrative of the general type and quality of goods and does not super set to the same to super set. Not not such model or sample furnished to Buyer is Description (Documentation, THEE WARRANTES) EXPRESS OR INNERING WITHOUT LIMITATION, IMPLIED WARRANTES OF MERCHANTABILITY, FITHESS FOR ANY PARTICULA PURPOSE, OR NON INFRINCEMENT. BUYER'S EXCLUSIVE REMEDY FOR NON-CONFORMING PRODUCTS DURING THE WARRANTED TO EXPLANCE FOR ANY DESCRIPTION TO REPAIR, REPLACE OR REFUND FOR REPUND FOR THE NOU-CONFORMING PRODUCTS IN A MANRER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS IN A MANRER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS IN A MANRER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS IN A MANRER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS IN A MANRER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS IN A MANRER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF

**Year** 2014